• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Highmark Covers AppliedVR’s RelieVRx for Chronic Back Pain

by Fred Pennic 09/09/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Highmark, a commercial health insurance plan, has announced coverage for RelieVRx, a virtual reality-based therapy for chronic low back pain. 

– This landmark decision makes RelieVRx accessible to over four million Highmark members.

A Breakthrough Treatment for Chronic Back Pain

RelieVRx is a fully immersive VR experience designed to empower individuals with skills for managing chronic low back pain (CLBP). Clinically proven to reduce pain intensity and interference, RelieVRx offers a cost-effective, non-pharmacologic treatment option.

How RelieVRx Works

Chronic pain imposes a significant economic burden on the United States, estimated at $635 billion annually. RelieVRx offers a potential solution for managing chronic back pain and reducing its associated costs.

RelieVRx features a 56-session program that addresses the bio-psycho-social aspects of pain. Patients use the device at home, completing daily VR sessions. RelieVRx has a user-friendly interface and has received high usability ratings in clinical testing.

Expanding Access to RelieVRx

Highmark’s decision to cover RelieVRx is a major step forward in making this innovative therapy accessible to more patients. Eligible commercial members aged 18 and older diagnosed with moderate to severe CLBP can now obtain a prescription for RelieVRx from their healthcare provider without prior authorization.

“Every individual battling CLBP deserves access to noninvasive, drug-free options that empower them to self-manage their pain. Highmark’s forward-thinking approach recognizes the promise of immersive therapeutics, and we are grateful for their collaboration,” said Matthew Stoudt, Co-founder and CEO of AppliedVR. “RelieVRx is based on decades of clinical evidence demonstrating the transformative potential of immersive therapeutics to reshape the body’s response to pain, and we are committed to building an even greater body of evidence that continues to set the industry standard.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Augmented Reality, Therapeutic Virtual Reality, Virtual Reality

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |